nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.02.2008 | Original Article

New T cell epitopes identified from an anti-idiotypic antibody mimicking ovarian cancer associated antigen

verfasst von: Wei Li, Heng Cui, Fan-Qiang Meng, Xiao-Hong Chang, Guo Zhang, Bei Liu, Zi-Hai Li

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Anti-idiotype (Id) antibodies can be used to induce specific cellular immune responses against tumor antigens, but the mechanism of antigenicity is not always clear. We previously reported an anti-Id antibody, 6B11, which mimics human ovarian cancer associated antigen OC166-9. To explore the molecular basis of cellular immune response induced by 6B11, a panel of peptides derived from complementarity determining region (CDR) of 6B11 were synthesized. After a series of immunologic experiments, we found that the light chain CDR3 peptide and heavy chain CDR3 peptide were the MHC class I and class II epitopes of 6B11, respectively. The combination of MHC class I and class II epitopes is more effective than 6B11 in inducing specific cellular immune response against ovarian cancer. Our study provided the structural basis of antigenicity of 6B11. The identification of antigen-specific T cell eptitopes in 6B11 should facilitate the design of epitope-based vaccine against human ovarian cancer.

Durrant LG, Maxwell-Armstrong C, Buckley D, Amin S, Robins RA, Carmichael J, Scholefield JH (2000) A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin Cancer Res 6(2):422–430PubMed

Pervin S, Chakraborty M, Bhattacharya-Chatterjee M, Zeytin H, Foon KA, Chatterjee SK (1997) Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res 57(4):728–734PubMed

Reece DE, Foon KA, Bhattacharya-Chatterjee M, Hale GA, Howard DS, Munn RK, Nath R, Plummer BA, Teitelbaum A, Phillips GL (2000) Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer. Bone Marrow Transplant 26(7):729–735PubMedCrossRef

Grant SC, Kris MG, Houghton AN, Chapman PB (1999) Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 5(6):1319–1323PubMed

Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89(2):466–470PubMedCrossRef

Foon KA, Lutzky J, Baral RN, Yannelli JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M (2000) Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 18(2):376–384PubMed

Cheung NK, Guo HF, Heller G, Cheung IY (2000) Induction of Ab3 and Ab3’ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res 6(7):2653–60PubMed

Wagner U, Kohler S, Reinartz S, Giffels P, Huober J, Renke K, Schlebusch H, Biersack HJ, Mobus V, Kreienberg R, Bauknecht T, Krebs D, Wallwiener D (2001) Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 7(5):1154–1162PubMed

Mittelman A, Chen ZJ, Kageshita T, Yang H, Yamada M, Baskind P, Goldberg N, Puccio C, Ahmed T, Arlin Z (1991) Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. J Clin Invest. 1990 Dec;86(6):2136–44. Erratum in: J Clin Invest 87(2):757

10.

Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S (1994) Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2–23. Cancer Res 54(2):415–421PubMed

11.

Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S (1995) Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1(7):705–713PubMed

12.

Quan WD Jr, Dean GE, Spears L, Spears CP, Groshen S, Merritt JA, Mitchell MS (1997) Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m. J Clin Oncol 15(5):2103–2110PubMed

13.

Saleh MN, Lalisan DY Jr, Pride MW, Solinger A, Mayo MS, LoBuglio AF, Murray JL (1998) Immunologic response to the dual murine anti-Id vaccine Melimmune-1 and Melimmune-2 in patients with high-risk melanoma without evidence of systemic disease. J Immunother 21(5):379–388PubMedCrossRef

14.

Pride MW, Shuey S, Grillo-Lopez A, Braslawsky G, Ross M, Legha SS, Eton O, Buzaid A, Ioannides C, Murray JL (1998) Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin Cancer Res 4(10):2363–2370PubMed

15.

Mitra-Kaushik S, Shaila MS, Karande AK, Nayak R (2001) Idiotype and antigen-specific T cell responses in mice on immunization with antigen, antibody, and anti-idiotypic antibody. Cell Immunol 209(2):109–119PubMedCrossRef

16.

Qian HN, Lu WY (1994) Anti-idiotypic monoclonal antibodies against anti-ovarian carcinoma monoclonal antibody COC166-9. Generation and application. Chin Med J (Engl) 107(2):99–103

17.

Qian H, Wang J, Feng J (1997) Vaccination with monoclonal anti-idiotypic antibody on immunocompetent mice bearing human ovarian carcinoma. Chin Med J (Engl) 110(4):259–263

18.

Li Y, Chang XH, Cui H, Yang WL, Feng J, Wei LH (2003) [Immuno-therapeutic study of anti-idiotype minibody (single chain Fv-CH3) on ovarian carcinoma bearing mice]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 25(4):451–456PubMed

19.

Yang WL, Cui H, Feng J, Chang XH, Fu TY, Ye X, Zhang H, Li XP, Wen HW, Feng LM, Tong CR (2004) [Induction of T cell responses against autologous ovarian cancer by anti-idiotype minibody-pulsed dendritic cells]. Ai Zheng 23(12):1639–1645PubMed

20.

Abrams SI, Schlom J (2000) Rational antigen modification as a strategy to upregulate or downregulate antigen recognition. Curr Opin Immunol 12(1):85–91PubMedCrossRef

21.

Dohi Y, Yamada K, Ohno N, Aoki M, Takagaki Y, Nisonoff A, Shinka S (1988) Naturally occurring cytotoxic T lymphocyte precursors with specificity for an Ig idiotype. J Immunol 141(11):3804–3809PubMed

22.

Chang X, Cui H, Feng J, Li Y, Liu B, Cao S, Cheng Y, Qian H (2003) Preparation of humanized ovarian carcinoma anti-idiotypic minibody. Hybrid Hybridomics 22(2):109–115PubMedCrossRef

23.

Guo HF, Feng J, Liu G, Cui H, Ye X, Yao Y, Fu T (2005) Establishment and characterization of a human ovarian sarcomatoid carcinoma cell line BUPH:OVSC. Int J Gynecol Cancer 15(5):856–865PubMedCrossRef

24.

Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50(3–4):213–219PubMedCrossRef

25.

Boyum A (1968) Isolation of leucocytes from human blood. Further observations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating agents. Scand J Clin Lab Invest 97:31–50

26.

Plebanski M, Allsopp CE, Aidoo M, Reyburn H, Hill AV (1995) Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. Eur J Immunol 25(6):1783–1787PubMedCrossRef

27.

Andersen MH, Tan L, Sondergaard I, Zeuthen J, Elliott T, Haurum JS (2000) Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 55(6):519–531PubMedCrossRef

28.

Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM (1995) Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154(11):5934–5943PubMed

29.

Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767–811PubMedCrossRef

30.

Cui H, Chang XH, Liu B, Feng J, Li Y, Ye X, Cao SJ, Fu TY, Yao Y, Li HQ, Qian HN (2004) The anti-tumor immune responses induced by a fusion protein of ovarian carcinoma anti-idiotypic antibody 6B11ScFv and murine GM-CSF in BALB/c mice. Int J Gynecol Cancer 14(2):234–241PubMedCrossRef

31.

Pride MW, Shi H, Anchin JM, Linthicum DS, LoVerde PT, Thakur A, Thanavala Y (1992) Molecular mimicry of hepatitis B surface antigen by an anti-idiotype-derived synthetic peptide. Proc Natl Acad Sci U S A 89(24):11900–11904PubMedCrossRef

32.

Chatterjee SK, Tripathi PK, Chakraborty M, Yannelli J, Wang H, Foon KA, Maier CC, Blalock JE, Bhattacharya-Chatterjee M (1998) Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. Cancer Res 58(6):1217–1224PubMed

33.

Murray JL, Gillogly M, Kawano K, Efferson CL, Lee JE, Ross M, Wang X, Ferrone S, Ioannides CG (2004) Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res 64(15):5481–5488PubMedCrossRef

34.

Wang RF (2001) The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 22(5):269–276PubMedCrossRef

35.

Rice J, Elliott T, Buchan S, Stevenson FK (2001) DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J Immunol 167(3):1558–1565PubMed

36.

Le Gal FA, Prevost-Blondel A, Lengagne R, Bossus M, Farace F, Chaboissier A, Gras-Masse H, Engelhard VH, Guillet JG, Gahery-Segard H (2002) Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study. Int J Cancer 98(2):221–227PubMedCrossRef

37.

Steitz J, Bruck J, Gambotto A, Knop J, Tuting T (2002) Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther 9(3):208–213PubMedCrossRef

38.

Toungouz M, Libin M, Bulte F, Faid L, Lehmann F, Duriau D, Laporte M, Gangji D, Bruyns C, Lambermont M, Goldman M, Velu T (2001) Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol 69(6):937–943PubMed

39.

Casares N, Lasarte JJ, de Cerio AL, Sarobe P, Ruiz M, Melero I, Prieto J, Borras-Cuesta F (2001) Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol 31(6):1780–1789PubMedCrossRef

40.

McNeel DG, Nguyen LD, Disis ML (2001) Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res 61(13):5161–5167PubMed

41.

Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM (2002) NY-ESO-1 119–143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res 62(1):213–218PubMed

42.

Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136(7):2348–2357PubMed

43.

Wassenaar A, Reinhardus C, Abraham-Inpijn L, Kievits F (1996) Type-1 and type-2 CD8+ T-cell subsets isolated from chronic adult periodontitis tissue differ in surface phenotype and biological functions. Immunology 87(1):113–118PubMed

44.

Birkhofer A, Rehbock J, Fricke H (1996) T lymphocytes from the normal human peritoneum contain high frequencies of Th2-type CD8+ T cells. Eur J Immunol 26(4):957–960PubMedCrossRef

45.

Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, Bhattacharya-Chatterjee M (2004) Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res 64:4995–5003PubMedCrossRef

46.

Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, Xiao F, He QM, Shu JM, Xie XJ, Mao YQ, Lei S, Luo F, Zhou LQ, Liu CE, Zhou H, Jiang Y, Peng F, Yuan LP, Li Q, Wu Y, Liu JY (2000) Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 6(10):1160–1166PubMedCrossRef

47.

McBride WH, Howie SE (1986) Induction of tolerance to a murine fibrosarcoma in two zones of dosage—the involvement of suppressor cells. Br J Cancer 53(6):707–711PubMed

Titel: New T cell epitopes identified from an anti-idiotypic antibody mimicking ovarian cancer associated antigen
verfasst von: Wei Li
Heng Cui
Fan-Qiang Meng
Xiao-Hong Chang
Guo Zhang
Bei Liu
Zi-Hai Li
Publikationsdatum: 01.02.2008
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 2/2008
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0354-8

Neu im Fachgebiet Onkologie

17.04.2024 | Mammakarzinom | Nachrichten

Springer Medizin

New T cell epitopes identified from an anti-idiotypic antibody mimicking ovarian cancer associated antigen

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells

PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting

CRMP5 antibodies in patients with small-cell lung cancer or thymoma

Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it?

Control of lymphocyte infiltration of lung tumors in mice by host’s genes: mapping of four Lynf (lymphocyte infiltration) loci

Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells

Neu im Fachgebiet Onkologie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Update Onkologie